Kineta (KANT) 8-K Kineta Completes Reverse Merger with Yumanity Therapeutics

Exhibit 16.1

December 22, 2022

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Commissioners:

We have read the statements made by Kineta, Inc. (formerly known as Yumanity Therapeutics, Inc.) (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Kineta, Inc. dated December 16, 2022. We agree with the statements concerning our Firm contained therein.

Very truly yours,

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts